

BEST WORLD INTERNATIONAL LIMITED

Company Registration No. 199006030Z
(Incorporated in the Republic of Singapore)

COMPLETION OF FIRST PHASE SUBSCRIPTION OF SHARES IN CELLIGENICS PTE. LTD.

The board of directors ("**Board**") of Best World International Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to the Company's announcement dated 13 January 2019 in relation to a proposed investment by the Group in Celligenics Pte. Ltd. ("**Celligenics**") in two phases, under which the Company or its designated wholly-owned subsidiary will (i) subscribe for new ordinary shares in the capital of Celligenics ("**Shares**") representing 12.5% of the total number of issued Shares on a fully-diluted basis (the "**First Phase Subscription**"), and (ii) have the right (but not the obligation), which is exercisable during a period of 14 business days commencing from the date immediately following 18 months from the date of completion of the First Phase Subscription, to subscribe for new Shares such that the Group will hold up to 15.0% of the Shares as at the date such right is exercised, on a fully-diluted basis (the "**Second Phase Investment**").

The Board is pleased to announce that the First Phase Subscription has been completed on 21 January 2019 and its wholly-owned subsidiary, Celcott Investments Pte. Ltd., has subscribed for all 115,165 new Shares in Celligenics, representing 12.5% of the total number of issued Shares on a fully-diluted basis. The aggregate cash consideration paid by the Group on completion of the First Phase Subscription was S\$5,625,000.

Should the Group decide to proceed with the Second Phase Investment or provide further funding to Celligenics, such further announcement(s) will be made when appropriate in compliance with the Listing Manual of the Singapore Exchange Securities Trading Limited.

On Behalf of the Board

Huang Ban Chin
Executive Director and Chief Operating Officer
21 January 2019